



Helping premature babies breathe

Each year, almost 1 in 10 babies are born prematurely in Australia. Babies born early face numerous health challenges, including needing help to breathe for weeks or months after birth. Supported by NHMRC grants, collaborating researchers from The Royal Women's Hospital, University of Melbourne, Monash University, Murdoch Children's Research Institute, and University of Tasmania implemented numerous programs aimed at improving the care of premature infants, leading to their improved long-term lung health.



Origin

Babies born prematurely have underdeveloped lungs with very little surfactant, a substance that is essential for lung inflation. As such, premature babies often have difficulties with breathing and require assistance.

Traditional interventions involved intubation and mechanical ventilation to deliver surfactant. This frequently damaged immature lungs and led to complications. Researchers began looking for an alternative to this invasive procedure.

Investment

Commencing in 1984, NHMRC supported research on non-invasive breathing support for premature infants through fellowships and program grants.

These grants were provided to a diverse team of researchers collaborating across The Royal Women's Hospital, University of Melbourne, Monash University, Murdoch Children's Research Institute, and University of Tasmania.

Research

In 1999, the research team began evaluating the safety and efficacy of continuous positive airway pressure (CPAP) as a non-invasive alternative treatment for premature infants with breathing issues. Following the success of CPAP trials, the team explored nasal High Flow (nHF) technology as a simpler and easier-to-administer alternative to CPAP in 2010.

From 2011-2020, the team developed and trialed their minimally-invasive surfactant therapy (MIST) technique to allow delivery of surfactant in tandem with CPAP and nHF.

Translation

Trials demonstrated strong clinical evidence for CPAP and nHF as a safer non-invasive alternative to intubation, posing fewer risks and requiring less training to administer.

Further investigation by their SHINE trial showed that adding nHF to intubation procedures resulted in more stable blood oxygen levels, increasing its success rates and safety for babies.


Infants who received MIST as newborns had lower rates of adverse respiratory outcomes during their first 2 years of life.

Impact

CPAP is now the first line of respiratory support provided for most premature babies in Australia and globally. Use of nHF treatments and MIST procedures also increased significantly in clinical settings.

Non-invasive treatments have improved newborn care and reduced the need to transfer premature infants to metropolitan neonatal intensive care units, decreasing burden on parents, the healthcare system, and saving approximately \$1,700 AUD per child.

Around 10% of babies born each year in Australia are premature.



ECF: Early Career Fellowship | IG: Investigator Grant | PF: Practitioner Fellowship | PG: Project Grant | PGG: Program Grant | RF: Research Fellowship

Researchers

Prof Colin Morley
Prof Richard Harding
Prof Peter Davis

A/Prof Lousie Owen
Prof Brett Manley
Prof Stuart Hooper

Prof Peter Dargaville
Dr Kate Hodgson
Dr Omar Kamlin

Dr Calum Roberts

visit nhmrc.gov.au
to read the full story

